Article

The Melbourne Consensus Statement on the Early Detection of Prostate Cancer.

University of Melbourne, Peter MacCallum Cancer Centre, Melbourne, Australia
BJU International (Impact Factor: 3.13). 11/2013; 113(2). DOI: 10.1111/bju.12556
Source: PubMed

ABSTRACT Various conflicting guidelines and recommendations about prostate cancer screening and early detection have left both clinicians and their patients quite confused. At the Prostate Cancer World Congress held in Melbourne in August 2013, a multidisciplinary group of the world's leading experts in this area gathered together and generated this set of consensus statements to bring some clarity to this confusion.The five consensus statements provide clear guidance for clinicians counselling their patients about the early detection of prostate cancer.

Download full-text

Full-text

Available from: Declan G Murphy, Mar 02, 2014
1 Follower
 · 
87 Views
  • BJU International 02/2014; 113(2):177. DOI:10.1111/bju.12605 · 3.13 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The estimated population of the world in 2008 was 6.75 billion people, increasing by around 79 million people each year. The world population is aging. In 1970, the world median age was 22 years; it is projected to reach 38 years by 2050. The number of people in the world aged 60 years and older is expected to almost triple to 2 billion by 2050. Because cancer, especially prostate cancer, is predominantly a disease of the elderly, increases in the number of older people will lead to more cases of cancer, even if current incidence rates remain the same.
    Urologic Clinics of North America 05/2014; 41(2):237-247. DOI:10.1016/j.ucl.2014.01.009 · 1.35 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Population screening with prostate-specific antigen (PSA) for detection of prostate cancer is a topic associated with ongoing dissent and confusion within the oncology and wider medical community. The PSA blood test has been used in various stages of prostate cancer management, including screening and the assessment of future risk of prostate cancer development, detection of recurrent disease after local therapy and in the management of advanced disease. However, PSA-based decision-making in prostate cancer has significant shortcomings. This review will summarise the evidence and current recommendations for the use of PSA in detection and management of prostate cancer.
    Internal Medicine Journal 05/2014; 44(5). DOI:10.1111/imj.12407 · 1.70 Impact Factor
Show more